Vanguard Global Advisers
SKYE icon

Vanguard Global Advisers’s Skye Bioscience SKYE Stock Holding History

Vanguard Global Advisers’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.16K Hold
4,557
– – ﹤0.01% 3586
2026
Q1 		$2.8K Buy
+4,557
New +$3.71K ﹤0.01% 3599

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's SKYE Position: Q2 2026 in Review

Vanguard Global Advisers held its Skye Bioscience (SKYE) position steady in Q2 2026 at 4,557 shares worth $3.16K. The position accounts for ﹤0.01% of the portfolio, ranked #3586.

Vanguard Global Advisers first reported a position in SKYE in Q1 2026 and has held it in 2 quarters since. 41 funds tracked by Wall St. Rank hold SKYE as of Q2 2026.

  • Vanguard Global Advisers held 4,557 shares of Skye Bioscience worth $3.16K as of Q2 2026.
  • Vanguard Global Advisers left its Skye Bioscience share count unchanged in Q2 2026.
  • Skye Bioscience made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3586 holding.
  • Vanguard Global Advisers first reported a position in Skye Bioscience in Q1 2026 and has held it in 2 quarters since.
  • 41 funds tracked by Wall St. Rank held Skye Bioscience as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.